<SEC-DOCUMENT>0001571049-14-007258.txt : 20141216
<SEC-HEADER>0001571049-14-007258.hdr.sgml : 20141216
<ACCEPTANCE-DATETIME>20141216081700
ACCESSION NUMBER:		0001571049-14-007258
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		4
CONFORMED PERIOD OF REPORT:	20141216
ITEM INFORMATION:		Other Events
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20141216
DATE AS OF CHANGE:		20141216

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Cyclacel Pharmaceuticals, Inc.
		CENTRAL INDEX KEY:			0001130166
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				911766850
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	000-50626
		FILM NUMBER:		141288350

	BUSINESS ADDRESS:	
		STREET 1:		200 CONNELL DRIVE
		STREET 2:		SUITE 1500
		CITY:			BERKELEY HEIGHTS
		STATE:			NJ
		ZIP:			07922
		BUSINESS PHONE:		908-517-7330

	MAIL ADDRESS:	
		STREET 1:		200 CONNELL DRIVE
		STREET 2:		SUITE 1500
		CITY:			BERKELEY HEIGHTS
		STATE:			NJ
		ZIP:			07922

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	XCYTE THERAPIES INC
		DATE OF NAME CHANGE:	20001218
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>t1402478_8k.htm
<DESCRIPTION>FORM 8-K
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0"><FONT STYLE="font-size: 10pt"><B>&nbsp;</B></FONT></P>

<!-- Field: Rule-Page --><DIV STYLE="text-align: left; margin-top: 0; margin-bottom: 0"><DIV STYLE="font-size: 1pt; border-top: Black 2pt solid; border-bottom: Black 1pt solid; width: 100%">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 18pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="margin: 0pt 0; text-indent: 0.5in"></P>

<P STYLE="font: 18pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-size: 18pt"><B>UNITED
STATES</B></FONT></P>

<P STYLE="font: 18pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>SECURITIES AND EXCHANGE COMMISSION </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Washington, D.C. 20549 </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 18pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>FORM 8-K </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>CURRENT REPORT </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Pursuant to Section 13 or 15(d) </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>of the Securities Exchange Act of 1934
</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Date of Report (Date of earliest event
reported): December 16, 2014</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 18pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>CYCLACEL PHARMACEUTICALS, INC.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>(Exact name of registrant as specified
in its charter)</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B></B></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; border-collapse: collapse">
<tr style="vertical-align: bottom; background-color: white">
    <TD STYLE="width: 32%"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-size: 10pt"><B>&nbsp;&nbsp;Delaware</B></FONT></P></td>
    <TD STYLE="width: 2%"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></td>
    <TD STYLE="width: 32%; font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-size: 10pt"><B>0-50626</B></FONT></td>
    <TD STYLE="width: 2%"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></td>
    <TD STYLE="width: 32%; font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-size: 10pt"><B>91-1707622</B></FONT></td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-size: 10pt"><B>(State or other
    jurisdiction</B></FONT></td>
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></td>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-size: 10pt"><B>(Commission File
    Number)</B></FONT></td>
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></td>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-size: 10pt"><B>(IRS Employer</B></FONT></td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-size: 10pt"><B>of incorporation)</B></FONT></td>
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></td>
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></td>
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></td>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-size: 10pt"><B>Identification No.)</B></FONT></td></tr>
</table>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>200 Connell Drive, Suite 1500</B><BR>
<B>Berkeley Heights, NJ 07922 </B><BR>
<B>(Address of principal executive offices and zip code) </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Registrant&rsquo;s telephone number,
including area code: (908) 517-7330</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>(Former Name or Former Address, if Changed
Since Last Report)</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Check the appropriate box below if the Form 8-K filing is
intended to simultaneously satisfy the filing </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>obligation of the registrant under any of the following provisions
(<I>see </I>General Instruction A.2. below): </B></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; border-collapse: collapse">
<tr style="vertical-align: top">
    <TD STYLE="width: 3%; font: 10pt Times New Roman, Times, Serif"><font style="font: 10pt Wingdings">o</font></td>
    <TD STYLE="width: 97%; font: 10pt Times New Roman, Times, Serif"><font style="font-size: 10pt"><b>Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) </b></font></td></tr>
</table>
<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; border-collapse: collapse">
<tr style="vertical-align: top">
    <TD STYLE="width: 3%; font: 10pt Times New Roman, Times, Serif"><font style="font: 10pt Wingdings">o</font></td>
    <TD STYLE="width: 97%; font: 10pt Times New Roman, Times, Serif"><font style="font-size: 10pt"><b>Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) </b></font></td></tr>
</table>
<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; border-collapse: collapse">
<tr style="vertical-align: top">
    <TD STYLE="width: 3%; font: 10pt Times New Roman, Times, Serif"><font style="font: 10pt Wingdings">o</font></td>
    <TD STYLE="width: 97%; font: 10pt Times New Roman, Times, Serif"><font style="font-size: 10pt"><b>Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) </b></font></td></tr>
</table>
<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; border-collapse: collapse">
<tr style="vertical-align: top">
    <TD STYLE="width: 3%; font: 10pt Times New Roman, Times, Serif"><font style="font: 10pt Wingdings">o</font></td>
    <TD STYLE="width: 97%; font: 10pt Times New Roman, Times, Serif"><font style="font-size: 10pt"><b>Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) </b></font></td></tr>
</table>
<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Rule-Page --><DIV STYLE="text-align: left; margin-top: 0; margin-bottom: 0"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid; border-bottom: Black 2pt solid; width: 100%">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt"><B>Item 8.01 Other Events.</B></FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24.5pt; background-color: white"><FONT STYLE="font-size: 10pt">On
December 16, 2014, Cyclacel Pharmaceuticals, Inc. (the &ldquo;<B>Company</B>&rdquo;) issued a press release announcing the enrollment
of 486 patients, continuation to final analysis and recommendations of the independent Data and Safety Monitoring Board (&ldquo;<B>DSMB</B>&rdquo;)
of the Company&rsquo;s Phase 3 SEAMLESS study of sapacitabine oral capsules in acute myeloid leukemia (AML). The DSMB determined
that the planned futility boundary has been crossed, but saw no reason for patients to discontinue from the study. A copy of the
press release is attached as Exhibit&nbsp;99.1 to this Current Report on Form 8-K, and the information contained therein is incorporated
herein by reference.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24.5pt; background-color: white"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24.5pt; background-color: white"><FONT STYLE="font-size: 10pt">Neither
the filing of the press release as an exhibit to this Report nor the inclusion in the press release of a reference to our internet
address shall, under any circumstances, be deemed to incorporate the information available at our internet address into this Report.
The information available at our internet address is not part of this Report or any other report filed by us with the Securities
and Exchange Commission.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><FONT STYLE="font-size: 10pt"><B>Item&nbsp;9.01
Financial Statements and Exhibits.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24.5pt; background-color: white"><FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
(d)&nbsp;Exhibits</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24.5pt; background-color: white"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%">
<tr>
    <TD STYLE="text-align: left; width: 15%; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; border-bottom: Black 1pt solid"><FONT STYLE="font-size: 8pt"><B>Exhibit</B><br>
    <B>Number</B>&nbsp;</FONT></td>
    <TD STYLE="text-align: center; width: 3%; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; padding-bottom: 1pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></td>
    <TD STYLE="text-align: center; width: 82%; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; border-bottom: Black 1pt solid"><FONT STYLE="font-size: 8pt"><br>
    <B>Description</B></FONT></td></tr>
<tr>
    <TD STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></td>
    <TD STYLE="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></td>
    <TD STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></td></tr>
<tr>
    <TD STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">99.1</FONT></td>
    <TD STYLE="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></td>
    <TD STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">Press release, dated
    December 16, 2014</FONT></td></tr>
</table>
<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-size: 10pt"><B>SIGNATURES</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">Pursuant
to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf
by the undersigned thereunto duly authorized.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; border-collapse: collapse">
<tr style="vertical-align: top">
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt"><B>CYCLACEL PHARMACEUTICALS,
    INC.</B></FONT></td></tr>
<tr style="vertical-align: top">
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></td>
    <td colspan="2"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></td></tr>
<tr style="vertical-align: top">
    <TD STYLE="width: 50%"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></td>
    <TD STYLE="width: 6%; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">By: </FONT></td>
    <TD STYLE="width: 44%; border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">/s/
    Paul McBarron</FONT></td></tr>
<tr style="vertical-align: top">
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></td>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">Name:</FONT></td>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">Paul McBarron</FONT></td></tr>
<tr style="vertical-align: top">
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></td>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">Title:</FONT></td>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">Executive Vice President&mdash;Finance,
    </FONT></td></tr>
<tr style="vertical-align: top">
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></td>
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></td>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">Chief Financial Officer and Chief Operating
    <BR>
Officer</FONT></td></tr>
</table>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">Date: December 16, 2014</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 3 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-size: 10pt"><B>EXHIBIT
INDEX</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%">
<tr style="vertical-align: bottom">
    <TD NOWRAP STYLE="width: 15%; border-bottom: black 1pt solid; font: 12pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 8pt"><B>Exhibit
    No.</B></FONT></td>
    <TD STYLE="width: 3%; font: 12pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></td>
    <TD NOWRAP STYLE="width: 82%; border-bottom: black 1pt solid; font: 12pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-size: 8pt"><B>Description</B></FONT></td></tr>
<tr>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></td>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></td>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></td></tr>
<tr>
    <TD STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">99.1</FONT></td>
    <TD STYLE="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></td>
    <TD STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">Press release, dated
    December 16, 2014.</FONT></td></tr>
</table>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 4; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>t1402478_ex99-1.htm
<DESCRIPTION>EXHIBIT 99.1
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0; text-align: right"><B>Exhibit 99.1</B></P>

<P STYLE="margin: 0"></P>

<P STYLE="font: 10pt Arial,sans-serif; margin: 0pt 0; text-align: right">&nbsp;</P>

<table cellspacing="0" cellpadding="0" style="width: 100%; border-collapse: collapse">
<tr style="vertical-align: top">
    <TD STYLE="width: 50%; font: 10pt Times,serif; text-align: left; vertical-align: middle"><font style="font: 10pt Arial,sans-serif"><img src="logo.jpg"></font></td>
    <TD STYLE="width: 50%; font: 10pt Times,serif; text-align: right; vertical-align: middle"><font style="font: 10pt Arial,sans-serif">Cyclacel Pharmaceuticals, Inc.</font></td></tr>
</table>
<P STYLE="font: 10pt Arial,sans-serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Arial,sans-serif; margin: 0pt 0; text-align: center"><img src="logo1.jpg"></P>

<P STYLE="font: 11pt Calibri,sans-serif; margin: 0pt 0; text-align: center">&nbsp;<FONT STYLE="text-transform: uppercase"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 11pt Calibri,sans-serif; margin: 0pt 0; text-align: center"><B>CYCLACEL ANNOUNCES ENROLLMENT OF 486 PATIENTS, DSMB
RECOMMENDATIONS AND THAT THE<BR>
 SEAMLESS PHASE 3 TRIAL OF SAPACITABINE IN AML WILL CONTINUE TO FINAL ANALYSIS </B></P>

<P STYLE="font: 11pt Calibri,sans-serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 11pt Calibri,sans-serif; margin: 0pt 0; text-align: center"><B><I>- DSMB determined that the planned futility boundary
has been crossed; </I></B></P>

<P STYLE="font: 11pt Calibri,sans-serif; margin: 0pt 0; text-align: center"><B><I>but saw no reason for patients to discontinue
from study -</I></B></P>

<P STYLE="font: 11pt Calibri,sans-serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 11pt Calibri,sans-serif; margin: 0pt 0; text-align: center"><B><I>- Conference Call Scheduled December 16, 2014
at 9:00 a.m. EST -</I></B></P>

<P STYLE="font: 11pt Calibri,sans-serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 11pt Calibri,sans-serif; margin: 0pt 0; text-align: justify"><B>Berkeley Heights, NJ, December 16, 2014 </B>&ndash;
Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP; Cyclacel or the Company), a biopharmaceutical company developing oral
therapies that target the various phases of cell cycle control for the treatment of cancer and other serious disorders today announced
enrollment of 486 patients, continuation to final analysis and recommendations of the independent Data and Safety Monitoring Board
(DSMB) of the Company&rsquo;s Phase 3 SEAMLESS study of oral sapacitabine capsules in acute myeloid leukemia (AML). All patients
will continue to be followed up until mature data become available for final analysis. The DSMB conducted its planned interim analysis
for futility after 247 events and the final safety review of 470 randomized patients. The DSMB found no safety concerns. However,
the planned futility boundary has been crossed and the DSMB determined that based on available interim data, it would be unlikely
for the study to reach statistically significant improvement in survival. The DSMB saw no reasons why patients should discontinue
treatment on their assigned arm and recommended that recruited patients stay on treatment.</P>

<P STYLE="font: 11pt Calibri,sans-serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 11pt Calibri,sans-serif; margin: 0pt 0; text-align: justify">&ldquo;At this stage all patients should stay on study&rdquo;,
said Hagop Kantarjian, M.D., Chairman &amp; Professor, Department of Leukemia, The University of Texas MD Anderson Cancer Center
and chair of the SEAMLESS study. &ldquo;It is essential that we have complete follow-up of all patients to ensure that the mature
survival data does not miss any potential survival benefit in the overall patient population or subgroup of patients.&rdquo;</P>

<P STYLE="font: 11pt Calibri,sans-serif; margin: 0pt 0; text-align: justify; color: #313131">&nbsp;</P>

<P STYLE="font: 11pt Calibri,sans-serif; margin: 0pt 0; text-align: justify; background-color: white">Judy H. Chiao, M.D., Vice
President, Clinical Development and Regulatory Affairs for Cyclacel said, &ldquo;We were surprised and disappointed to learn of
the outcome of the interim analysis for futility suggesting that it is unlikely that the experimental arm of sapacitabine alternating
with decitabine will be superior to the decitabine control arm in the final analysis. We agree with the DSMB&rsquo;s recommendation
to keep all patients on treatment and complete the study, as the DSMB advised that response rates were similar between the arms
and there was no evidence of adverse outcomes for patients on the experimental arm. We thank the DSMB for their work and especially
the patients and clinical investigators in the U.S. and Europe for their support of our efforts during the last three years to
enroll SEAMLESS, one of the largest studies in this population.<FONT STYLE="color: #313131">&quot;</FONT></P>

<P STYLE="font: 8pt Arial,sans-serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 11pt Calibri,sans-serif; margin: 0pt 0; text-align: justify">The interim analysis for futility is primarily driven
by the deaths within the first 6 months of patients entering into the trial. Of 247 deaths in SEAMLESS, 173 (70%) have occurred
in the first 6 months. This means that the survival curves beyond 6 months are poorly estimated at this time. Furthermore, follow
up of European patients is significantly shorter than that of US patients due to the fact that the study opened for European accrual
in April 2014. It is important to have complete follow up of all patients to ensure that a potential treatment effect beyond 6
months is not missed.</P>

<P STYLE="font: 11pt Calibri,sans-serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 11pt Calibri,sans-serif; margin: 0pt 0; text-align: justify">The Company remains blinded and in accordance with
the DSMB&rsquo;s recommendations, will follow-up patients as per the study protocol until the prespecified 424 events have been
observed. This is estimated</P>

<P STYLE="font: 11pt Calibri,sans-serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 8pt Times,serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Wingdings">&thorn;</FONT></TD><TD><FONT STYLE="font-family: Arial,sans-serif">200 Connell Drive, Suite 1500, Berkeley Heights, NJ&nbsp; 07922 USA T: +1 (908)
517 7330 F: +1 (866) 271 3466 </FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 12pt Times,serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font: 8pt Wingdings">&uml;</FONT></TD><TD><FONT STYLE="font: 8pt Arial,sans-serif">Dundee Technopole, James Lindsay Place, Dundee, DD1 5JJ, UK Tel +44 1382 206 062 Fax
+44 1382 206 067</FONT></TD></TR></TABLE>

<P STYLE="font: 7pt Arial,sans-serif; margin: 0pt 0; text-align: center"><U>www.cyclacel.com</U> &ndash; <U>info@cyclacel.com</U></P>

<P STYLE="font: 11pt Calibri,sans-serif; margin: 0pt 0; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: left; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 11pt Calibri,sans-serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 11pt Calibri,sans-serif; margin: 0pt 0; text-align: justify">to occur between
the second half of 2015 and the first half of 2016. The Company has adequate financial resources to reach beyond the later time
point in this estimate. Depending on the results from the final data, the Company may meet with regulatory authorities in Europe
and the U.S. to discuss registration submissions for sapacitabine in this indication. The Company wishes to draw investors&rsquo;
attention to the precedent of decitabine&rsquo;s European approval in AML in a similar population based on a Phase 3 study which
did not reach statistical significance comparing intravenous decitabine with intravenous chemotherapy.</P>

<P STYLE="font: 11pt Calibri,sans-serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 11pt Calibri,sans-serif; margin: 0pt 0; text-align: justify; background-color: white">&ldquo;Absence of
early benefit in this Phase 3 study does not preclude emergence of a late benefit with longer follow up. As the well-being of
patients is a paramount concern and the DSMB recommends that patients remain on study, we are encouraged that patients on the
sapacitabine regimen are not disadvantaged to those on the control arm,&rdquo; said Spiro Rombotis, President  &amp;
Chief Executive Officer of Cyclacel. &ldquo;We have sufficient capital resources to follow up patients, reach the final
analysis of SEAMLESS and continue existing programs through 2016. The feasibility assessment for our Phase 2b randomized
trial of sapacitabine in myelodysplastic syndromes (MDS) is in progress. Obviously, we will review and consider any impact of
the SEAMLESS interim analysis on our plans for the MDS study. Our emerging cyclin dependent kinase (CDK) inhibitor
program continues to progress as planned. This includes the Phase 1 study of our oral regimen of seliciclib in combination
with sapacitabine in Homologous Recombination (HR) repair-deficient solid tumors and CYC065, our novel CDK 2/9 inhibitor,
with potential utility in both hematological malignancies and solid tumors.&rdquo;</P>

<P STYLE="font: 11pt Calibri,sans-serif; margin: 0pt 0; text-align: justify; background-color: white; color: #313131">&nbsp;</P>

<P STYLE="font: 11pt Calibri,sans-serif; margin: 0pt 0; text-align: justify">The SEAMLESS study is a Phase 3, randomized, registration-directed
study of oral sapacitabine capsules in elderly (70 years or older) patients with AML who are unfit for or have refused intensive
chemotherapy from approximately 110 U.S. and European sites. SEAMLESS has enrolled 486 patients and is one of the largest studies
in this population. The primary endpoint is overall survival. SEAMLESS is comparing a regimen of oral sapacitabine alternating
with intravenous decitabine versus a control of intravenous decitabine. SEAMLESS is being conducted under a Special Protocol Assessment
(SPA) agreement with the U.S. Food and Drug Administration (FDA). Sapacitabine has orphan drug designation in the U.S. and Europe
for both AML and myelodysplastic syndromes.</P>

<P STYLE="font: 11pt Calibri,sans-serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 11pt Calibri,sans-serif; margin: 0pt 0; text-align: justify"><B>Conference call and Webcast Information:</B></P>

<P STYLE="font: 11pt Calibri,sans-serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 11pt Calibri,sans-serif; margin: 0pt 0; text-align: justify">Cyclacel will conduct a conference call on December
16, 2014 at 9:00&nbsp;a.m. Eastern Time to discuss the Company&rsquo;s plans with regard to SEAMLESS. Conference call and webcast
details are as follows:</P>

<P STYLE="font: 11pt Calibri,sans-serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 11pt Calibri,sans-serif; margin: 0pt 0; text-align: justify">Conference call information:</P>

<P STYLE="font: 11pt Calibri,sans-serif; margin: 0pt 0; text-align: justify">US/Canada call: (877) 493-9121/ international call:
(973) 582-2750</P>

<P STYLE="font: 11pt Calibri,sans-serif; margin: 0pt 0; text-align: justify">US/Canada archive: (800) 585-8367 / international
archive: (404) 537-3406</P>

<P STYLE="font: 11pt Calibri,sans-serif; margin: 0pt 0; text-align: justify">Code for live and archived conference call is 54535033</P>

<P STYLE="font: 11pt Calibri,sans-serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 11pt Calibri,sans-serif; margin: 0pt 0; text-align: justify">For the live and archived webcast, please visit the
Corporate Presentations and Events page on the Cyclacel website at <U>www.cyclacel.com</U>. The webcast will be archived for 90
days and the audio replay for 7 days.</P>

<P STYLE="font: 11pt Calibri,sans-serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 11pt Calibri,sans-serif; margin: 0pt 0; text-align: justify"><B>About Cyclacel Pharmaceuticals, Inc.</B></P>

<P STYLE="font: 11pt Calibri,sans-serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 11pt Calibri,sans-serif; margin: 0pt 0; text-align: justify">Cyclacel is a biopharmaceutical company developing
oral therapies that target the various phases of cell cycle control for the treatment of cancer and other serious diseases. Sapacitabine,
Cyclacel's most advanced product candidate, is the subject of SEAMLESS, a Phase 3 trial being conducted under an SPA with the FDA
as front-line treatment for acute myeloid leukemia (AML) in the elderly, and other studies for myelodysplastic syndromes (MDS)
and chronic lymphocytic leukemia (CLL).&nbsp;Cyclacel&rsquo;s pipeline includes an oral regimen of seliciclib in combination with
sapacitabine in a Phase 1 study of patients with Homologous Recombination (HR) repair-deficient breast, ovarian and pancreatic
cancers, including gBRCA positive tumors, and CYC065, a novel CDK 2/9 inhibitor, with potential utility in both hematological malignancies
and solid tumors. Cyclacel's strategy is to build a diversified biopharmaceutical business focused in hematology</P>

<P STYLE="font: 11pt Calibri,sans-serif; margin: 0pt 0; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: left; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 11pt Calibri,sans-serif; margin: 0pt 0">&nbsp;&nbsp;</P>

<P STYLE="font: 11pt Calibri,sans-serif; margin: 0pt 0; text-align: justify">and oncology based on a development pipeline of novel
drug candidates. Please visit <U>www.cyclacel.com</U> for additional information.</P>

<P STYLE="font: 11pt Calibri,sans-serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 11pt Calibri,sans-serif; margin: 0pt 0; text-align: justify"><B>Contacts for Cyclacel Pharmaceuticals, Inc.</B></P>

<P STYLE="font: 11pt Calibri,sans-serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 11pt Calibri,sans-serif; margin: 0pt 0; text-align: justify">Company: Paul McBarron, (908) 517-7330, <U>pmcbarron@cyclacel.com</U></P>

<P STYLE="font: 11pt Calibri,sans-serif; margin: 0pt 0; text-align: justify">Investor Relations: Russo Partners LLC, Robert Flamm,
(212) 845-4226, <U>robert.flamm@russopartnersllc.com</U></P>

<P STYLE="font: 11pt Calibri,sans-serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 11pt Calibri,sans-serif; margin: 0pt 0; text-align: justify">&copy; Copyright 2014 Cyclacel Pharmaceuticals, Inc.
All Rights Reserved. The Cyclacel logo and Cyclacel&reg; are trademarks of Cyclacel Pharmaceuticals, Inc.</P>

<P STYLE="font: 12pt Times,serif; margin: 0pt 0; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 3; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 12pt Times,serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 12pt Times,serif; margin: 0pt 0; text-align: justify">&nbsp;</P>



<P STYLE="margin: 0"></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>logo.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 logo.jpg
M_]C_X``02D9)1@`!`@``9`!D``#_[``11'5C:WD``0`$````9```_^X`)D%D
M;V)E`&3``````0,`%00#!@H-```&U```%U<``![````FCO_;`(0``0$!`0$!
M`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0("`@("`@("
M`@("`P,#`P,#`P,#`P$!`0$!`0$"`0$"`@(!`@(#`P,#`P,#`P,#`P,#`P,#
M`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#_\(`$0@`0P"T`P$1
M``(1`0,1`?_$`0X``0`"`P$!`0`````````````&!P4("00#`@$!``(#`0$!
M``````````````,%!`8'"`$"$``!!`(!`P,"!@,````````$`@,%!@$'`$`2
M$Q$4%2,($#`A%A<X,2(W$0`!!``$`P4#"`<%"0`````#`0($!0`1$@8A$Q0Q
M42(5!T%A,A!Q0E(C,R060')#4R4U=C"!DK07D;'18J(T1&4($@`!`00$"0H"
M!@@'```````!`@`1`P0A,1(%0$%A<8&1(E(34:&QP3)"8H(C%/`&T:(S0U,5
MX7+"TH.C)"7QDK+#-$0U$P$``@("`0,$`@(#```````!$2$`,4%184!Q@1#P
MD;&AP='Q(##A_]H`#`,!``(1`Q$```'OX1"SIN=G;?-U>W>N8G)P\OC9G0?B
MOHN_-.Z$```````(=9TO,GOGEN2X%I";:CBMC42'"L<EBYVS?F_U]NH`````
M``<].U><O3^)8[FUL8L*OQ2P9FNMH]QKT+M5676VP`````!\S#FEW7N!0RUI
M9O4WEPZQNF+_`%'AM4WF]<*RL`TG/D;8E!E9%WFPQIR;?&G1G2I380N@UF(K
MUKA'HCFL>CV39+1>FQHDH***@-O3AP;%G5(YNG2(XT%G%LENFCA,SJ(#6C?.
M8>&;'E5=;670[1[HI\IC9?NBG\)S7-QBER=%*F&)02PB)!BU"DB0&RYLL4IM
M6COOSX?J/)097FDBS>)GSZFV#(0Y(```````%(;9HGX^_)37VHP&97^V*>V]
M;W`````````:_P"Y\[K2^UCV138/,P-V^3]T````````_]H`"`$!``$%`N3<
M]%5T&=W3.R;ZX#;MBYFF;0AU1NUKU7B*?L2!N">@GYP&N1045/[7E&K1X'Y6
MOR[BQZVREP^>LT5R/UT[(/Z[WW0MFS_Y^P5%7>\6=IVP2Z>Z2'`A(5UJ3B!6
M&:]#O,-E35W:L=$TCKS7,W^:I24)^2C_`$U?ELLR+;-9U_(1\>A8]$9E$GT&
M$B$M5\F=+K%6@*9#<E-XP29D_=/Q%7Q.1&82%VY6Y"B-;Q*.:?V-&,7/FSMU
MUK5AS3K;[4WNR!#G`]I]U>B][R4T#(;&C([8DF#B2`_BYOV^LP7/X\B6<*K`
MP_H=PV*#DE?AL^2.AM<_;S%1D7I\\`.4!&@;8J>V^!'D;*Y;O[,_XY6B:;L^
M?U7?9$W1'VU1L<!IW<?_`"G4ELW,/1+7_:O\*LGX6XQT6KVB'4G-BGN>')KJ
M^#DL%-\)&8,&AZ!MS4_*0_L,D9FBSZ-][3UH+LF&:*^YD%K8-2V>[L,M_?$Y
M4*OHG6D+7*UJ\RD[6B]=[3U0^9&;7M]#I[?W%T^L;&INS'MJT:1VH:9RX11K
MF',,6N/%?:EB\]["NYI[GN'XU(I&"Q^AD(*1BST2=9M*TQ,R+Q4?9'N/"UBM
M*CI.<FCNBV!X_CP?#X'_`#^.K^R_<W0__]H`"`$"``$%`N"!D&NB540=&#*T
M%SY2ODX?KL0:B3A#(S/0!B.G$.D!UT=4?WH'-&QA9RLX9#`(X1/(&:Z"%\<3
M$@*2$-GT86\44E3!+BU21S*$EF$'/=!8/5MHA32IEEY[.%RZA\IG'W,/D/$Y
MZ&>>Q\V2KT/6OZ722&?=1CQ'U,IRUEQE/=XDXXM"F\]#&$-8XGOCGG$*&;_1
M6/\`9/.Q#^7$>-?0LEL$,Y8/C\9)%<YAX%/$N'GX?8$%:Z*&]?,[W=Z.SUD/
M+[#H?__:``@!`P`!!0+AQXD:P?=SRG%1]QDN?"6H/(MMGHYR&L@$SCH)`]B-
M$8$D+<4F5[%EQQBLMQB,*(D)03@E8<,>Z"Q9=G9V42J1,QZDMC@@J24&TVB'
MC"'5@1XD:/T%5REUX1+Z*\0..E3<`@K"ZT,SD808-/0U=A7[<$3ZQ;3?U^DB
ML>RFAA<^'"\/I:(5V>=6>-N(=3T,R(^KBO'+CM.),>_5&?5*^>18V&G/,WT)
M`!(I&"HN55@,UKF1Y-?%M1<9D8HXY_HK%V^W8[/&YY.V*\'R?0__V@`(`0("
M!C\";@RR;2_BMN+>*[1SV4C36>9G0S!?X1:YW%K*U0G>)+ND-;E]@\J"\:JN
MAK2]J7WAU\F`IEH/;5S96$E)IXD^K%C)Y5=0;WWS+'HQ0WN`R48\B=;?VJ1B
M*1O60@:RW];(Q>'F3$Z&,Q<D7@QQ79JS+AEEREZPB)NS4*4+?C&0X#$OB+]J
MNA'QE->0,KYAG]N<BGTQU_%0SLF:O-)F;YB]B#B0,5&+XREG7C.HEU?APDVB
M,YI:S(7@%Q=R,ES]-!94680J6OQ'9L][34I)RMQYE5J)@,G=*.Z@/SFCZ63`
M7_PI""]V5(?TNU-[JU9O";*C;_"@IK(U49`W#NL"%"WG`Q%95*/0*FX=XI3,
M0<M"AF4*0P5&4I3@X/+Z,"@3'W=F&K0][7DCO*AGF4D]#"SCD@!H7M=>"RTZ
M.T@&$K12GF:#>SGPXB;$090+*AYDTAA+/#TFU"5B4E6(Y^8O!K9R=E6ZJAWQ
MK;;4-%):RL.5@2Y*:+I2.'$[JNZO1CR,N1GDOEU=H?Z5HZN44-8B>M=Q.RH8
MLQ[JN5!_2SH<5"D<D0.(Z1J4S^+`ACPTGF!/.&]O)(4N(:U&O54D<I).=BAX
M+N2D8$).\7V$]B(.TC(=Y&2L8FXT`VY57>3M(/ZPZE!O5@"UX"4\VT&H@E7Z
MR_W0EO;RB'0MU`</,?WBQ0M?$G3N]A&<]XYJ!RX&;/N7N^Y=]9]#F]?V7\2S
M:T\)O3_+;7F_;H;U?=>7A\#^7@7_V@`(`0,"!C\"8S,XL(A].0#&6X%T0[`Q
M%UI9T5#G9\83!'B59&IXZ&MPT1G^!;^@MPIOU`.[$#E:Z#K>UB&;$WC0:]&]
M\48"N<F3Z:1K.(#*65>5X+X5V(QXDC=0_P"LK_!C=OR=+4XXKGJ.5YJ&56H-
M_>[SA(B;MM2S_E30&?=MYP#&SKA<Y82GS)`]Q*FHJ[6>'%'TEH<_<<8&1MO>
MJA<,BL$8R,E>`PK@@%T"'M1#SDZ$U95,CY4NKT[O@I!BD8AR?%:C34RY&Y5"
M3^7H/VL?'$(KIK/QD#/NF[HDTC\:,JRDY0*`0Q7>=U&'`_$EUOLZ'J3K<R8,
MK$3.?+47M!7<\M:5CPUM[6339@O?IP&?OV)WHA<?"-H]3*F4?^C><Q9?D6HC
MHM:V]E9M75(!($/\:87V0<SZ<IY&$6^B8\?<>1"1X4I#JJGE[VXUT+5*3&1Z
MD'(I!+B-3%,LA*`HO-D.>>7`IF5^^MQDG/9<USQ>XF*G64+'2QM5"\B3IA['
M2EV"SEW&A,0B.C,JA>I33%Q/LQH2^)!/A*K:#Y5O26,W9-E0LQT=Y"TU*&5/
M.FRH5,"K;1B4FD'0*NAG0T'.K9'TZFMPR]&!0[RD0^?EB\#?0>VC2*LK0KSN
MU0$VCLD_6AQ!R8CC!I#<2"?;WND;:%8QE'?3NK3^AK46!$1$-9A%X/0=:6=P
M9F,?'0G3:(',6]W>,1$.$*`A-6NM:N0`#,6$5R@\5$..D8$9^Z'<17VD(T(B
M91NQ,M1[S"7FAPYY/<7L1$GPGK07-Z,RHIY(B0OG%E6LMM3*4CP0Q^T5=#>[
MGHCX^)<55I7D&+,A+")#A\&[AOC;B9D]Q.-ZMH\@P--KV5E__8?]2S2_,W]-
M^8_PK5CR\?%S,>-^;V?)_M[3>C[+S\7W/\WJP+__V@`(`0$!!C\"P^QMY8XD
M9G!%=Q(8F6:"`)N9#%=W(F%A;3K^C8YVD1B`Z^T-QX.9&:CP`U)[,B+[\:Y8
M[Y[')JRGS1UXOJ\`$,!!_P"%,<^/#N4>B+F2LLFR7Y?-%E/(O]R8Z:U<ZP:-
M<BPKF,X$IJ)P73(:P,AKO>[6F$#'>L&U:S46KE.;SN'Q.BDX,EB3_E\2>U$_
M09=O8OTQXK,]+<N8<KO"*.%%^(IGKDG_``Q)W%?2_*MM0G$SD.<C8\2./Q.B
M5S2?9J1K/O3NX9]N?PX?MSTAVZCG-31(OGQNHFR?HJ?FR,F!`JIP>=<NYB8<
MN]/4BKA251=<$EE,MI`U1>(R1(6D(LL^Q,(NW?4BE?+S\(WR;.@(]S>+4860
MG+<OZRHF!57J)2)N"L)]R:<@UFHQ?V]/N"+FA'HG'BYV?MRQ"W)L^["NWAR$
ME.FSB/BVE*L1Z%DADB$->:>,Q."M5-2>Y<\66W-N%LTL*\)90EL(21@V<(!!
MA-+@N88SM#'E;X2H)^2YZ>W+^WJ=APB/9!K],RV*SL8]XT*4J^S5&AO1K,_V
MA<0O2W;"I74%/'"7<,D.6@(6:7H`B\$>K,T545?M#/\`%\*XF4NSI(MI;`I7
M.'>;L>NB3;G$W(ZLD*HRGU+W*F>?<K68<[:GI[/W.%O'\Q;GGNKH4IR+DXH`
M/=&$43E7W+WIAYMR^EY*Z$JYON-HVBG2(Q."O?':27#5$S^GH3&H5O7;D]*C
M#/(N26YF1FT0HP7G,0X#E::LGQ$R76%4:Y%S5$QL.#Z*U%-N#TAN'?QZT!RK
M&-(*^P-%OTL[`\CJ8+X4$:<KX5>_P^/+1BRW!M>J/&LK$9(^N3,-+9!B&(PI
M8E>POW`2$$W//4_AEJRX?VSGO<UC&-5SWN5&M:UJ9N<YR\$:B8SZV+W_`'P\
M\N7S=66>>GE>+/LT\>S&_-\'\74V$D8#+P1(@$=-*B<5TII4>?ZN)5B!=.X?
M4O<"0VR,_M1@LIA0IDOA=H'&:5W#Z^/)DBND[6V**OBAJ!*B?F7>%@C%B1I/
M[QH>>UQ$7AK*JKP3`Y>\CDNISFHJ5S#GC4-6G#*)7P([PM(P*>'F%U.)EGCS
M/;UH39<D3QHZ2V4XE09"F8Q`3X$Z1TI1G>]&M1%9XE3'3P80]N[*ZS==1O?:
MUMMN.`F\UD1F0H]I72A27OCUA7YN&]-*O9[.Z-M_;-:*JJ(:E<"&(ARHUQRN
M,9[C22GD%>0CU55<Y5^2=M[:&W]T^HEO5DY%HW:-<.365A]2L4$ZYE2(T$96
MO3)=*O1%SXYHN+/=-UZ>[\IX]%80(=U#L*Z&*3%BSU<UMQ$<V:^/95@"(C2O
M&[-BN[,N.$W)YA&\B6M\X\S5^47RSINKZS7^YZ?Q?-@GJ/;LE;4VOSC)#DWJ
M,&>?%87D1YD:+'<<SVV!45`#R4K\L].6/,:?TD]5+6@5&D';AHH8%E1W=DF!
M6R;$<Z8!R<45&\4QM'9+Z^S;8;PHYM[".081!A@@QWR"1YXW%YXY2M8J:4:Y
M$=V_)25]S"MK`]N,LLOE00F2JK`28\1]G8\TXE'%Y\C),L\U:N!F"]I!&8PH
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M4X`C6D)I-:_M)%;91Q_W]2N2>]<$YK<D%ZB2),AKTS7\13*VN)WHU2%%I5?;
M\GX]G615#RGULIHI%:5[9,>6&26(4;VOE1C1FJ-WT?G^7?-K6/<*PK]JWDJ&
M5J*KA2!5QW"(S+CJ&[BGOQLI:Q@_XG5MMK$[4^TE6LY[B3B'?\1"B*G*S7L:
M-$]F)E;81QRX,^,:',C%34(\:0-PC">GU7C<J8)_\MOEN_*$>R7=!;]);VV+
M_3)2,ECVTFG-R2"6C^0KN[V<O'_SYL:2$`=GNL[>4M3RUZ`TFA@0VTL,@L^6
M\0]7+:U<^#U3V_)Z2_T=O#_*SL9KCUFW3NC<-#$A;@CR?3/:H;"XKHIP;=K6
M?B+,`BR&F8R?:JR0-WUF+VXW(,4ALO=?IM5;CVX<D<_4<V110I*T\X!FZVF$
M2&P>AZ*Y'J-<;4DP6-Y]P.9;6TG4A#2[0\Z0.0607XGD8T+6<?A1N6/4/^D+
MW_(&QL*#6^D];/V\RGJ(\>\?O:JC&/69,9Y@M:1O/$_D>/E+XO9CTQ_H"\_W
M[A^7>.WW^`5B4&Z:MO8QX9C4CV2#3@GV,QJ(N6-P['YG33*R:MWMP[NQ(<F;
MYG62&9<7M@6C7A+[<D]Z8+;=.5HY(F0-TUH]:S:VQ@<13`,9J(XT)R]K>)`\
MLC<]*9L<5O6B<B<FPKT20*2U5TM>X(E4@B?6R1S/?[,*D>(;@[)Y935B`&U/
MB>JD3FD3+LTM5/>F.=&(TPE5S6D9Q8[0NE58[L>W-.U.'R2(<H3#QI02QI`"
M)J&8!V.$83T]K"#<J+B75^FL_;.Z]CEEFEUFV]W&G0;6AZDG--%@6L1K@R(N
MM5^\]JYZ<]2NGF]08.V*V0Z0/RN'MJ5/FH*+R_M?,)$UK6OD*7LY?ATXF>H3
MF1?RX;80MO,)U*=9YBR>.0K5BZ<T%RV_%GB''98R*'<-%/9<;7W%#35(J+06
M6EZL1PU+&-I36U'-7-K7(N;<-KGU/I;>&8Q!LW$ZQNH`C9<.HF5;`M?S5^D@
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MT=0[5DU$F)<6KH(>KFELN<C>6WFN8,4U%:O?B<WU`VYM>DA,C#=7EH;:18F-
M*4N11G8;@,;1<47O^2OW%2BYM[MTKY`(Z+I\SKRIILJER]\D*9C[B-3OQ6[D
MV[*&&UAH1\`YFNTYN\$ZDM@ID1`D<W05OQ"(U'MXIQ<>(]VWMV1A#99UDIB$
M22)F>ELD*.&VR@YY\F6%R.:B]J<68>^51V$22_B65M^1SXQW9\2*,9(YGO<J
MY_:1U7WXT)3;CMG-=FUMHY8\/5QR4K)L@`%9FG[IZ^['FNX;&)6Q!,Y0:V(N
M<5BOX,0AWC;(L):HF3&#8Q.YKEXX#)01P(9B$04H2@D,1W8A0N\0WY>Q>*?H
M1K[:G*Y\EW,N*"03DUURN674@)DJ5]ODGWF6@GT^_`X%D!T"[C>-E=9:ZR[A
M%]I($@;QD(WA]Y&(YCDQE"W'(()$\`;>%&L,NY%DA6!+(B)]9[G>_&1-Q1XS
M<^*U],)A%;[?'/E6#&N[ETX;;7=CSIS<^387DSJIF:]K*Z-\`7NS^&*%JK@,
MF/`=4;>%K<I+,*LM;=58YH^1"54=70VN75K+]J_++0B<?T,'-_)_+YOB_-G4
MY99M_EW1_BNJ_4XX;Y=_J%EI9_(NO\KU9?\`B?FKQ\K_`*<$ZO\`U9Y6GC_+
M<NW_`-)^,_V<<L?@_P`FY<-7F7Y@_.N>I_P^?>/_``</T+__V@`(`0$#`3\A
MS9+39@/0*G/+!+DOSH8:=D8&Z9/:>K#R?0ZU7CR`D6%))"-"+GB<1(A-"AGX
M<C(0D1HO86`7Z')=W^,"D1HM&V`I"`J6FN)#&IDR0*+\4B=IB&OQ<EP"`+>C
MW-Z",9;]#FF[G5M5M8J-*;\5BN!VR6"8AJ.V-`9$M"LWI0HQIY*8AZ`DX+">
M5WA?IX#I2]H0YK05$R7T$HLR;05XE&&1H"]13[NKDG*F>F:/%\H6$#H)+H)S
M2$!"*^%M[EP.-G&`2H!MJ[H<$HC_`-U/V)F<807*M!GME3_4K]^6PR0$7G*@
M'I0,GC%]2*F%]"#[2)(=XCC<E"$UC%)9C:(G5'L@&CC6%4`5L%2)8,&FK466
MLB^GA6'/-H3;1X>G<!](MGQ,?!S(0"!!1SLQNUW$ZO("``DLJV]<O?2<HMUM
M[G"@!@D%(W!\&F6::8&"<KZ!T&*_*BA?0H*I-<M3)E%["0&-`.&Z*AY'!!C4
M*,E5%E4:F2MDSIK$$"F5@UJ"F@!980LP)\A\1[>[/)R()@4G"H4R2U(F<\6K
M?9CZ^MBO0$3%!7-#VQE0OZ/$LBZ`-X,$4P260&D\*1Q](R9BT7YHS=U"B?08
M;?BVF1HQ8)R2@LR%<ME1=!!G<DO.<^Z<WB<.Y(6:'O4X@RD.&I%`:@86)$.J
M/H-4"@`*JP`6JN@Q"38[B%R,`J8)WW(V98P9<4QP$\353,$+4?#Z4IJW[5*,
M-LAD<G_AA"5IE$>#RAEH1>\T)-[/E-(A0C)(SEM4&X-(.I1F3R,B%1%#0E%"
M4F7M0Z$"!S8[V8#;<<]87&8'7%/TFQ/J%#HBN1QB>3&],&(5T"\4`'U0J^]E
M=%WD2WJ=;!.G%.(9E#*T`OZQ`!C[VWQ07.,-&`3#W8JUTMS$4#"#5--HLG:)
M^P,`I%NO5RMH*#'05250GA!&(P\<[GC78R()M6)H]'LA,AD2$<#'1'J*7906
MUCL\K8N0'8H(AQ=[IA'`I02T^EN(J!_,+#FDY86Y#@$>RK\0'"O0M,@LO5`B
M;,M7>P)/RJ`.6\0V",0F95LCR0L9D2>P,I<#.R1F+B5[)NR8Q<@->B6W3DF8
MD8`FC`Y2]L`@(;?TCQ+QEY1"+K!@VV.7AIO)=A`=$AQR.1.Z$#K9!B%P1#E;
M"SKQDSQ<%/HWV*<OPG+&>[TZ3_71KGC%KIW\W?M,^]5+OS_HCT7_V@`(`0(#
M`3\AP.Y?P':T'ERJ;V'R5/R>S*]!VK\)/SA[52-_&9$\37[R?PED8IFM?L-O
MWKI?0E7+?`Y7@+_]RG8?)417'7?4;R`A*P^"6?`GM82.%ASR7OSD=-W!'N6_
M`YT+Y*_P!\'B<FG`0@`PBUY)CWKT(#!JGD&`^%<-QNC;5J'4ZK36F0?!)6CE
M8^0Q[F$L1_402'\G6$>([+T0_'.#P>UB_4V4ER(EQA.0)@`#0!0>A%92![1^
MW>6<>#(_R4<3P%E=KQ)D>"%N+"EV\!AA=TFF3KOJ,X32'F<6FW$@:)?1<U1W
MRX5?B8Z6Q/,N$?"_!/TN[O:8[OO/"_?;KNJ?-[.2,F+\XS4>=4Z42*1;L>$M
M)U,>'.%W5HO>*H^7X<ENZ'9/?7L^B7ADZ%^Y7D<2\@@?E6I-K2*IH"(\OB3O
M9XK"\-8(Q3KV`E`/]&1:2+_59CXO.6%2=M&X#V4'8*Q'5J)4GL\GGT58(@$^
M`^P>.+QTF$_2"'LDRP"MO\HA^`/&6[WE3\*_G&DUW\OV)Y?!:1J<V7^'CWQK
MT?W['VC67MDOV<G^<H\S[_Y\\H_I>S\^B__:``@!`P,!/R'!)'O:Z%IT?K+\
MEA/AK^U#\Y:0W5U;0_AC%:>2?\[DO'<_#"2_!XRJ")6>Y>A[6<CT,'36Y3Y2
M4?EHR2AW>"VA20VURRQB[84W6\'H6.LD:QVP_#^`/C"G0"Y>(I?E,\!D-/DW
MGDYC'ND!EP(QX2C3AE]`ER$#A3Y#!++KLHP0R[BE%]\9+B*+1&E9/"3)8.,+
M:Y?=2L?#V9SP%1.T_P``Q;G.JN)V==#64P;P%#E"55;595]^`/0W/1?</X/X
MY2KYX>`,!58BAFYUO+H2\JR$Q>X-/)7"=FC+&1U5VP>4R.APYW,8%W`[]%QO
M^%>!J()GI']3W,AB[7^=^;'/I2]JL70'L%9RFF>%^P_!#LR+*,D\""U.KN,!
M@W-T[VV+N)VLUCMJ-A!VW;X/N9#\RPFF*IY/)7H@9`?:Q?S=21O#(%'4NC+D
MD.D7%I$&AIBU<<LZ0=EY9_+IUW`LOG?+B.)#1_&1WS>,KV_`9U*#B!.DO#&+
M-2?<L?#??HKUK*_<7W6'.-ALDG:&BGFHYRB,Z_8J^1[<K?`D_DY@O'_T!I3T
MEU&+<EW%5!S?```F?1_)1\/V9REI@\O\N'@'^WW1>>+<^4ZW_3T7_]H`#`,!
M``(1`Q$``!`'6G@```````+_`')````````PW3X```````"!G0$$``D``$G0
M@$@D@``@@$E@PD`@`@`D`1?,8````````NM6`````````LL````````'_]H`
M"`$!`P$_$,9C2H\%U5QT3`@[."SM`]!+,LS%&"B`'V9RF>ZDM=UK+NA4<A*T
M83&]*P`<4`()9F4!@&YSSE@J\_0VM#@#ON142+X95%9`D[K%E*'-M18N;SM)
M>R&V\?2=Q$TB)+"#D^IM.06P+$(.`U[R(A1IPK,`$XK^G5J\3JO",G)(T_H#
M$:Z0'H`4KC1`R%(+"B-.(^$:%2":NVEQHWL+L-W;-VSE#^_"0OH/"4LEF5RL
M",E(8L:0B4_>RXWDQT,1ON2"L.B?!5/*E3CJ8Y8*2X!_[KJ5)"ACJL`50,ZP
M^]0S[Y9&@,M<M</*12E$X[4Q5A).-`D`8GH_+-,!G\S'XJR%J!%V#K*9(Y'L
M?C>%H2*H8]#2$C\[4Z7#;"=?"-4_@4!]&J%.PX,#AX*_N%NCBUX[@RGP'"#`
M<"<T`VT8[89UGN7!1$2%:D8V4DJ[:+`,S9PC-F%`+$_1.QH)!2HG(4`RT6HK
MQ2E14!,HK,Z>L`PNI<8SQ^M1=DCG!0"]SRT\P=<DK`#F'W%QXH*D,L!#-SI>
MD;JM6?MF3U."VYUTD8&D%)#@<X'R<"@+F*YA%6#'6`8`4K!3.Z[8/^O['32G
M@E#F=+5ZDID@*-8>Z/94#E""'001(W[6,E5*`D(PX5X-*,J%2Q*:1AV&E?FJ
M@.D8```````@`H`*`/HQ.@YX<H``)5H,EDM/C8Y?I')@2(;3SH^T6["$A($F
M"W+$]J87,%[N"UQ\;]#SUP:J*@_X/S6/Q`,\9`-L[(;$"0KQ%Z;*P9'@*&F;
MZ''C.4&*4"\#O#D&B5%*3_5'(6%4$$-Y;(.\AK`JD/H"&Y-ECC#I9SD@ONU_
MX,^F7)^1?F<E]!L8T#<8,0@3&$7*:`$M!E-X',8I?"&$0;:<X1,]%IR!SE"&
M2@!P!\S.G`&:/D?[7EX;F'A,-HNC'QAJND5UOXUB*!07<>R3(,`8%G:WM%E(
M$@X5AE&63R[!]:AJBLHNWKD[RZYRF73A:^*`(%MDC61%M6@<'?C1\4+]>N3\
M5I0(R#('FS32.`Q3P1H'5V:U\`H9<E`_T5K")]700TTD;),M9#[H!&=&"!+*
MJ%FH(1Z$E6D,87,2@T=Q)2S2T[4S`-.,5A#^"4L2P%=5N$I``W!+DB"1T,"U
M";I(WJ">N@RU`40E:RQ)-<]%X+/>K]Y@YS[*(1R/B^)S^JT/;V']XRYS/][$
M9YY]$?_:``@!`@,!/Q#+'O,5RFP/E#HE03L,3K%I6`\PO;%)C1/:[0]T[K#S
MC2%?F`\J@9#(LFHMDI9V.#DK$0XPSOJTGJ2:]"J?9RS!MIHRG;HE`Q+;`"V8
MU)JT(()<A2/(66Q:4#R\#@4@)3E9XMAVLN(C<L*-*J)W(BT"\'45:#'3J-*1
M\$1@9"TRT;3+0IB$A'H)>;[I`_,.1W8`KR&V07""$:]PR`8PDID01BW0,"":
M"$1CI1!Y\DRB,.`"!UL$%6(DO"P61(4$B#"QI$$4X;%`H6`E8"U5E5]#?`&;
M9)=$LC.Y3A`2CCU"LV1;([F!H5UDCMIH0R`)QS2"8MRJIK9(+M?FIJ&T#Z5R
M)DG.'3.Z#*/`2WRJOHKH9-[_`'U_.`,K?_@!%7P+K&M"<H*'SM*2Q,\^E2V0
M=I**VY"\B'61=#3;;X4EGTI;R-$2!*J,`RA%G$Q`PYFJPE!GE2$"FP!%,E"&
MB#FG<2%E!C<#!:H$@-J'@3D/13+D`F7('3^69(1B2.0DP6&QOG8S"$7@*-)A
M01-`E@Q0K^(Y1H>``C'IK!M0")%4A1;4B&1A5+T05D@95$$,EAQAT=!M.NH4
M[%+]%PB`SS-P9E;[58]H8Q'2*[;I@F\MFFU^T-"\':!BK#-!5XL1V1GA,JB9
MKTUIJ)C")D;R'T`&$#%$4'G"ICT;X!MLP_W_`!3G]$@S_E9WSX,.6O\`5I.\
M^:HXD;?^GYGT7__:``@!`P,!/Q#*X!C)BJ2D10+RP%%DWO!ZD23D+JX-%.A[
MP.KQHO&Y(9BHJ(=G@!7C)$CAP@I@#HB:Y7(]T2)31P':Q*_0V[!4(G(`I(@:
M+01(1'5#D(&(A@J@"9F:*0K5$I(BXD2,SF3T;C8)J3H09*B%'9""3=1)H5K%
M0QUF5N?"*#P$&<2]R<F)@8@`4P7H;>\E`2CB"?(,38$-J1Y!RH`-&PJBRH4&
MRU45,B>R<<RW&R(+%P&R<2M65"%+#"9A8%&J0'*"-5EBX!`#C5!C+U@"4P!`
M`>@HT*]`(BV"1:H,28ID46M<9HL%07@A`J60B/H;<$?P!!ZH/J@82%"H$H!9
M+-L$A3)(`888P`$T*8-1,"M``4>BIX`[JC?9@]L,3;UR.<6SD$-U@M``A+8:
M5"X@,(FO2@O#S0D=14@-0O;(TV.H?`7!G8"LF',CUZ.64*6)ADS``(8@P(/-
M(-$%1M1@(#+1,,:A+38AX>%N8IT2""*BE]%'9PF($MRC9-.%.&3\\P800>\;
M\<%85`9,#&:CQA-F704VW6WH580G5.6;T0HVB@A-QI(1C:!K2U`Z``W9(P$:
M<5$=&@K8!H#(>AY/AS8ACI$`1K#"BVNA<N^BH53!C*W4R(="P0Y3VN"$X6H3
MFW.D4<CEN^EBNX).18EA!DW:BQ:I5`J4)0+T;]%9B?Z/R1&?XFN?X"-/&>(6
18K'VGBUGO^=O\A^Z(]%__]D_
`
end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>4
<FILENAME>logo1.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 logo1.jpg
M_]C_X``02D9)1@`!`@``9`!D``#_[``11'5C:WD``0`$````9```_^X`)D%D
M;V)E`&3``````0,`%00#!@H-```#U0``":````P)```.>__;`(0``0$!`0$!
M`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0("`@("`@("
M`@("`P,#`P,#`P,#`P$!`0$!`0$"`0$"`@(!`@(#`P,#`P,#`P,#`P,#`P,#
M`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#_\(`$0@`%P).`P$1
M``(1`0,1`?_$`+<``0`"`P$``P`````````````&!P,%"`0!`@D!`0``````
M```````````````0``$$`P`!!0$!```````````!`@45`P0&$"!`<!(34!01
M``$#`@4#`@0$!`<```````(!`P0`!1$2TY0U$"$3,4%1(C(482,5!B!`4#-Q
M@9&A4V,D$@$```````````````````!P$P$``@,``@$%`0$````````!$2$`
M$#%!45`@0'!A@:%Q_]H`#`,!``(1`Q$```']_````````"#E#G6`.&CMT]!S
M$=%&S.?BW22%*$R)R`#F<L(M8J0S%JE=FP)H0,@Y>AY#EPZN!RV=2`Y4.I3,
M````````````````#2GV-P"FRWS*5P3P]9!20FY(F923@`@IZR7D6!*30FL)
MB:0T9-R/$-+3!5I:0*Q+*,@```````!"3&``````````````````````````
M`````````#Y/_]H`"`$!``$%`O8]+D?B@.6;L+(^,N7]]O%^GY'8K]NBT\;,
M6H=LW;3+$9=//&';8Y!^ISFQ';,1Z.OSZC.BXYN^D,=R]^/F.2PX,<>=8YS.
M;YURN@3IW.9SW#8L->9\S-?#R<CL,F_$B]-+JO'1?7-V3&HUG\*1TF26C'Z;
M8_2\9>,TLN-B*UA+<\DGOX,;L6$F8?++-C]'7C-,EH[/(XXB)U871]&]`ZLA
M)PD2V$TB9B\4U'14?FCL))Z#)2/AHK)$X"1TF26C"Q&2'PDKH)*1^3D8O]?&
M_P`PV4W/$AS?^R6:BM;[%TRK77:EVI=J7:EVI=J7:EVI=J7:EVI=J7:EVI=J
M7:EVI=J7:EVI=J7:EVI=J7:EVI=J7:EVI=J7:EVI=J7:EVI=J7:EVI=J7:EV
MI=J7:EVI=J7:EVI=J7:EVI=J7:EVI=J7:EVI=J7:EVI=J7:EVI=J7:EVI=J7
M:EVI=J7:EVI=J7:G_]H`"`$"``$%`OE[_]H`"`$#``$%`OE[_]H`"`$"`@8_
M`E[_V@`(`0,"!C\"7O_:``@!`0$&/P+^1N[C1DVX$%]0,%RD*Y?5"3NBU97;
M6W<`B%;"*_.R4DI#?D$'Y9-+(7!Q[R>X=L.M]!I^8O[C/]P%'L9`^^""#;F+
MC:FI)&1D0]47O3?F5%=\8>51^E7,J9U3\,W2Q,.-3I4=R+*\L.WF02'\%7#)
ME<:Q45[^OI49ML'6P!AH0;?52>`4!,`=55)5<'W[^O2V276)<NP1_,5UCP7"
M;>S8)XGG,A"9--_XX5"=M[ANPR8#P&X1$YD3Y<'"/$U<%4P7'WZ0CC-29,!F
M7Y+O%AFK<E^(@^@D/SY!7UPJ,Y:B>6'\X@,@S-YHD-<[3BN$18MDOQ7M_#96
M[HX\EJ2!.>E-ME(RXACD<48ZY\1+#O0E--PP<D/.6_S.(Z^EM-46*CIHI8EE
M_P`T3I<C;,FS1&,#%5%4_P#0U[IWK.S#N,0GO"3OZB9&KYHP'Y\?,Z[@P>;M
MZ=+P0$H$D,\"%50D[CZ*G=*M!$JD16^*JDJXJJ^(>ZJOKTO!"2B207U0A7!4
M7+ZHJ>E#(&+<F7W8T7SR)KADQ,+`E\L-"=<3QX_@/1Z0ZN#;#9NFOP!L5(O]
MDH#ER?*/[GAR+@VVKN;[9]F2Z0,Y<RY%6+[=7'_W&$_[!]^(-DG1WW0AQ%'#
M%IX&B'N9_5CC_IU:COQ[E.C+9P/[2VN&+V?RNX.X"ZS\H^_>@%,401$41>ZX
M(F"8K\?Z'*@.&382V39(PPS"AIAB..*8U%@@9.!%8;8$SPS$C:8(I8=L>LX?
MNI(NR[JEW:D!XT=AR4_X%R_0J?&A$BSD@HA&J(F=43N6"=DS=(5R"?*@2H+;
MC;)QQ9+^[]2JCP&F.%--FZ;Y@`B3SB"ANDB8*X2`B"A%^'1&QNLZ`RK;C,AF
M+XLDEMS#,AYP)4+#MBGLM1X$45%B,VC;:*N8OBI$ON1$N*]&VV+G,MBBIYRB
M>/\`.$QRJ#B."7I[8>BTU`AY_$VI$I.+F<<<-<QN&O9,Q+_#$N3YFJQ8LJ)]
MM@*LO-2Q('/)BF;T+VI(#<EZ0PVX91_/ES,-FN;P"0HF+8+Z8])%M><-IN1D
MS&WESID<%SMF14[Y:5EVX29X_EBS]P+`^!ML,B-AX6PQ3M[XKTE6]TR;;EM*
MT1AAG%%P[CFQ3'M7VRW"3.9`6FXXR!9'[=MH<J`'B;!514^./25`<,FPELFR
M1AAF%#3#$<>V-?;_`*E*FQP:;:CLR`8$8X-X_0K38$N*+[X^G25;R><CC*;\
M1NM9?(@*J9D',BI\R)A5K?B`EO?M;P.B[%::$I*"*"H25R_F(:)W]^HO3KG/
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MWS8IK5P]\V*:U</?-BFM7#WS8IK5P]\V*:U</?-BGX?]U?_:``@!`0,!/R'[
M%H$%1W"@#WDBD%AQH9;_`#IVT+*,$@^GPT0808<*`(#X<H_6B>IY&-'"`5:8
M1QH(B#@J:IW2H^)T@449>`C*2.3J"JXV5`2EAH;)I[N'1`4VX\*+0IBZZ\H"
M"D,?20&CI5IGR'/-9Y@1N"&D4%4`ZMP"V9L."NXKN92(;.%2_K3[+VUZ*$QM
MX"ED9!2Z8-L@ZD`HRYD[&1PDC*=BM2<-_P`BOY@T@80]RQ<\?YM@I!A3$1X^
MDEA4F@WH#\2AZ/O].X3:4J(P95`7\'.8J_/!&%^\@]2(.Q4F#QM]3\JYJHHA
M)3_,66U@B"WB)@K4>,?^*T>1.1#@1U^&T1DE@$ZOU/5OBS8)T/.2VG!`*C[1
M/;JWF(KQH8VX-F%UP/3UB>B`%?2[Z3!)'9&B1@A^2=J)`E\A.C)^1H2HW*-G
M,%:A#H%I4"NI/-S^ND!_U,@?B+,(Q$3=6C,5<IX(L7[P15+"6$6X,]$*&RI:
MB3.5<<[7#XYJ;0]GWLZQ(4Q#@M[E=[H'``=??+?\R,D+88$`!26*^R\[R2ZI
M%"1]?#4Z=.G3ITZ=.G3ITZ=.G3ITZ=.G3ITZ=.G3ITZ=.G3IT_@Z=.G3ITZ=
M.G3ITZ=.G3ITZ=.G3ITZ=.G3ITZ=.G3IEGB)]MB#WO\`S/_:``@!`@,!/R'\
MO?_:``@!`P,!/R'\O?_:``P#`0`"$0,1```0``````````$`D`@```D$@$$@
M@``$@```````````````````@D$`$``$$@$$@D````````````DDDDDDDDDD
MDDDDDDDDDDDDDDDDDDDDDDDDDDD__]H`"`$!`P$_$/L;.K0^CHE!$P:$"%U>
MM%K8$L8``ZTEZXW'#V#U!N*(-"*1I+K8Z##9:%DOQD6,TEDM_9*DKNH&DD)5
MP.ABR@:D[7T0,&`4E[HWV5P3`E5\JQQ;7[`U+81+=0?I@6%W^G78`@]$L;6E
ME#EBJ$1!(,0^$CB@`J2#8IA3([>P]$4$68T1>;B2#0CT1QL/6LY96E55=/",
M3!DRKB(F`:BJ;>=@F,&K1L6:`26J$K_N%X'19.*!,&L$3`T(220+>AN`X1"(
M(R-B6(\1U,'$0%XCFBPTA&%[O&<DO0E5;5^#"T#"248;4$PZ1AE5!5Z`/6QI
M9@KQ,L1J$*R(*1>4FT'I@!8*U,Y/A&QD"DOV+QNQW,5;J,=,`5I=H2H,D:.1
MA@98[.K89R&$0"T`0&0\=R9Q#LI.6:Q$@P[TL0N$@"#Z93ZXGW(0T%[P"7,*
ML#L3"3)B`R5!AY@0X2DLQ>0]?!M]F]`#NBT0:@!$#2"9+P%?9O73.G#W4UHC
M59%'R"8NBYC!-"H5A$7J_NPQ+Y')2/%Y(D0YE](55LXVVRG4RFJW236BE@``
M$!0%`'`-/,AAY`DU-*#$7A"#&835D``6@/LHV(@\6'N$B4,'PW__`/\`_P#_
M`/\`_P#_`/\`_P#_`/\`_P#_`/\`_P#_`/\`_P#_`/\`_P#_`/\`_P#_`/\`
M_P#_`/\`_P#_`/\`@_\`_P#_`/\`_P#_`/\`_P#_`/\`_P#_`/\`_P#_`/\`
M_P#_`/\`_P#_`/\`_P#_`/\`_P#_`/\`_P#_`/JY/+'^K>\>EG__V@`(`0(#
3`3\0_+W_V@`(`0,#`3\0_+W_V3\_
`
end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
